SAS® BI and JMP® Signal Detection of Adverse Drug Events in the FDA/AERS Database
David Olaleye, PhD, SAS Institute
Objectives:
Evaluate the performance characteristics of two disproportionality analysis (DA) methods for predicting drug safety signals in FDA/AERS and employ SAS© BI/JMP software to produce interactive graphical plots and tables to aid interpretation of the signal detection and data mining results.
